Novel compounds for the treatment of varicella-zoster virus infections

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 3, 2004, Pages 355-365

  Visalli, Robert J ^a  

^a INDIANA UNIVERSITY PURDUE UNIVERSITY FORT WAYNE   (United States)

Author keywords

Antiviral; Bicyclic pyrimidine nucleoside analogue (BCNA); Carboxamide; Herpesvirus; Thiourea; Varicella zoster virus

Indexed keywords

2 FLOURO N [4 [3 [1 (4 FLUOROPHENYL)ETHYL]THIOUREIDO]PHENYL]BENZAMIDE; 3 (2' DEOXY BETA DEXTRO RIBUFURANOSYL) 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURANO[2,3 D]PYRIMIDIN 2 ONE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 [2 (PHOSPHONOMETHOXY)ETHOXY]PYRIMIDINE DERIVATIVE; ACICLOVIR; ANTIVIRUS AGENT; BAY 571293; CHICKENPOX VACCINE; CIDOFOVIR; CYCLOHEXENE DERIVATIVE; DNA POLYMERASE; ENZYME INHIBITOR; FAMCICLOVIR; FLUOROURACIL; FOSCARNET; FOSCARNET SODIUM; ISOQUINOLINE 1 CARBOXYLIC ACID[4 [3 (1 BENZOFURAN 2 YL ETHYL)THIOUREIDO]PHENYL]AMIDE; N (CHLOROBENZYL) 1 METHYL 6 (MORPHOLIN 4 YLMETHYL) 4 OXO 1, 4 DIHYDROQUINOLINE 3 CARBOXAMIDE; N [2 CYAN 4 [3 [1 (4 FLUOROPHENYL)ETHYL]THIOUREIDO]PHENYL] 2 FLUOROBENZAMIDE; N [4 [3 [1 (4 BROMOPHENYL)ETHYL]THIOUREIDO]PHENYL] 2 FLUOROBENZAMIDE; NAPHTHACENE DERIVATIVE; NAPHTHACENEDIONE DERIVATIVE; NUCLEOSIDE ANALOG; PENCICLOVIR; PNU 181465; PNU 183792; PNU 26370; SORIVUDINE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION; VIRUS STRAIN;

EID: 1642369884     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.3.355     Document Type: Review

References (92)

1. ARVIN AM: Varicella-zoster virus. Clin. Microbiol. Rev. (1996) 9:361-81.
2. COHEN JI, BRUNELL PA, STRAUS SE, KRAUSE PR.: Recent advances in varicella-zoster virus infection. Ann. Intern. Med. (1999) 130:922-932.
3. AEBI C, AHMED A, RAMILO O: Bacterial complications of primary varicella in children. Clin. Infect. Dis. (1996) 23:698-705.
4. GNANN JW: VaricellA-zoster virus: atypical presentations and unusual complications. J. Infect. Dis. (2002) 186(Suppl. 1):S91-98.
5. ENDERS G, MILLER E, CRADOCK-WATSON J, BOLLEY I, RIDEHALGH M: Consequences of varicella and herpes zoster in pregnancy: Prospective study of 1739 cases. Lancet (1994) 343:1548-1551.
6. SNOECK R, ANDREI G, DE CLERCQ E: Novel agents for the therapy of varicella-zoster virus infections. Expert Opin. Investig. Drugs (2000) 9:1743-51.
7. PROBER CG, GERSHON AA, GROSE C, MCCRACKEN GH JR, NELSON JD: Consensus: Varicella-zoster infections in pregnancy and the perinatal period. Pediatr. Infect. Dis. J. (1990) 9:865-869.
8. TENSER RB: Herpes zoster infection and post-herpetic neuralgia. Curr. Neurol. Neurosci. Rep. (2001) 1:526-532.
9. KOST RG, STRAUS SE: Post-herpetic neuralgia-pathogenesis, treatment, and prevention. N. Engl. J. Med. (1996) 335:32-42.
10. WOOD MJ: How to measure and reduce the burden of zoster-associated pain. Scand. J. Infect. Dis. (1996) 100(Suppl.):55-58.
11. WOOD MJ: How should we measure pain in herpes zoster? Neurology (1995) 45:S61-62.
12. TAYLOR CE, SVILAND L, PEARSON AD et al.: Virus infections in bone marrow transplant recipients; a three-year prospectus study. J. Clin. Pathol. (1990) 43:633-637.
13. TAPPERO JW, PERKINS BA, WENGER JD, BERGER TG: Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin. Microbiol. Rev. (1995) 8:440-450.
14. ALLIEGRO MB, DORRUCCI M, PEZZOTTI P et al.: Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV serovconversion study. Clin. Infect. Dis. (1996) 23:990-995.
15. SMITH JB, FENSKE NA: Herpes zoster and internal malignancy. South Med. J. (1995) 88:1089-1092.
16. WINGARD JR: Management of infectious complications of bone marrow transplantation. Oncology (Huntingt.) (1990) 4:69-82.
17. DRUCKER JL, SMILEY L: Herpesviruses. In: Zinsser Microbiology, 20th Edition. Joklik WK, Willett HP, Amos DB, Wilfert CM (Eds), Appleton & Lange, Connecticut, USA (1992):959-961.
18. GROSS G, SCHOFER H, WASSILEW S et al.: Herpes zoster guideline of the German Dermatology Society (DDG). J. Clin. Virol. (2003) 26:277-289.
19. CHARTRAND SA: Varicella vaccine. Pediatr. Clin. North Am. (2000) 47:373-394.
20. CENTER FOR DISEASE CONTROL: Morbidity and mortality weekly report. (2002):51.
21. BREUER J: Vaccination to prevent varicella and shingles. J. Clin. Pathol. (2001) 54:743-747.
22. LEVIN MJ, BARBER D, GOLDBLATT E et al.: Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect. J. Infect. Dis. (1998) 178(Suppl.1):S109-S112.
23. EDMUNDS WJ, BRISSON M: The effect of vaccination on the epidemiology of varicella-zoster virus. J. Infect. (2002) 44:211-219.
24. BRISSON M, GAY NJ, EDMUNDS WJ et al.: Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine (2002) 20:2500-2507.
25. LARUSSA P, STEINBERG S, MEURICE F et al.: Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J. Infect. Dis. (1997) 176:1072-1075.
26. BRUNELL PA, ARGAW T: Chickenpox attributable to a vaccine virus contracted fiom a vaccine with zoster. Pediatrics (2000) 106:E28.
27. UEBE B, SAUERBREI A, BURDACH S, HORNEFF G: Herpes zoster by reactivated vaccine varicella zoster in a healthy child. Eur. J. Pediatr. (2002) 161:442-444.
28. LEVY O, ORANGE JS, HIBBERD P et al.: Disseminated varicella infection due to the vaccine strain of varicella-zoster Virus, in a patient with a novel deficiency in natural killer T cells. J. Infects. Dis. (2003) 188:948-953.
29. LEVIN MJ, DAHL KM, WEINBERG A, GILLER R, PATEL A, KRAUSE PR: Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J. Infect. Dis. (2003) 188:954-959.
30. DE CLERCQ EC Antiviral drugs: current state of the art. J. Clin. Virol. (2001) 22:73-89.
31. ENRIGHT AM, PROBER C: Antiviral therapy in children with varicella-zoster virus and herpes simplex virus infections. Herpes (2003) 10:32-37.
32. VAJPAYEE M, MALHOTRA N: Antiviral drugs against herpes infections. Indian J. Pharmacol. (2000) 32:330-338.
33. SNOECK R, ANDREI G, DE CLERCQ E: Current pharmacological approaches to the therapy of varicella zoster virus infections: A guide to treatment. Drugs (1999) 57:187-206.
34. WASSILEW SW, WUTZLER P: Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: Results of a randomized, double-blind, multicentered study. Antiviral Res. (2003) 59:49-56.
35. WASSILEW SW, WUTZLER P: Oral brivudin in comparison with acyclovir for herpes zoster: A survey study on post-herpetic neuralgia. Antiviral Res. (2003) 59:57-60.
36. JOHNSON RW: Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes (2003) 10:38-45.
37. HASWGAWA T, KUROKAWA M, YUKAWA TA, HORII M, SHIRAKI K: Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Res. (1995) 27:271-279.
38. IDA M, KAGEYAMA S, SATO H et al.: Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res. (1999) 40:155-66.
39. IDA M, KAGEYAMA S, SATO et al.: Characterization of acyclovir susceptibility and generic stability of varicella-zoster viruses isolated during acyclovir therapy. J. Dermatol. Sci. (2000) 23:63-72.
40. GILBERT C, BESTMAN-SMITH J, BOIVIN G: Resistance of herpesviruses to antiviral drugs: Clinical impacts and molecular mechanisms. Drug Resist. Update (2002) 5:88-114.
41. VISALLI RJ, VAN ZEIJL M: DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res. (2003) 59:73-87.
42. ACHESON DW, LEEN CL, TARIQ WU, MANDAL BK: Severe and recurrent varicella-zoster virus infection in a patient with the acquired immune deficiency syndrome. J. Infect. (1988) 16:193-197.
43. SAFRIN S, BERGER TG, GELSON I et al.: Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. (1991) 115:19-21.
44. VISSE B, DUMONT B, HURAUX et al.: Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J. Infect. Dis. (1998) 178(Suppl.1):S55-S57.
45. DE CLERCQ E: Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochem. Pharmacol. (1984) 33:2159-2169.
46. KIMBERLIN DW: Acylcovir derivatives and other new antiviral agents. Sem. Ped. Infect. Dis. (2001) 12:224-234.
47. NAESENS L, DE CLERCQ E: Recent developments in herpesvirus therapy. Herpes (2001) 8:12-16.
48. ERIKSSON B, OBERG B, WAHREN B: Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus. herpes simplex vinus and cellular origin. Biochim. Biophys. Acta. (1982) 696:115-123.
49. ELION GB: The biochemistry and mechanism of action of acyclovir. J. Antimicrob. Chemother. (1983) 12(Suppl.B):9-17.
50. FRANK KB, CHIOU JF, CHENG YC: Interaction of DNA polymerase and nucleotide analog triphosphates. Adv. Enzyme Regul. (1985) 24:377-394.
51. WHITLEA RJ: Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Neurology (1995) 45:S73-S75.
52. DE CLERCQ E, WALKER RT: Synthesis and antiviral properties of 5-vinyl-pyrimidine nucleoside analogs. Pharmacol. Ther. (1984) 26:1-44.
53. WUTZLER P, DE CLERCQ E. WUTKE K, FARBER I: Oral brivudin versus intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double-blind trial. J. Med. Virol. (1995) 46:252-257.
54. DE CLERCQ E, DESCAMPS J, DE SOMER P et al.: (E)-5(2-Bromovinyl)-2′-deoxyuridine: A potent and selective anti-herpes agent. Proc. Natl. Acad. Sci. USA (1979) 76:2947-2951.
55. DE CLERCQ E: Antiviral activity of nucTeoside analogues: the BVDU connection. In: RecenC advances in nucleosides: chemistry and chemotheraphy. Chu CK (Ed.), Elsevier Science, New York, USA (2002):433-454.
56. DE CLERCQ E: In search for a selective antiviral chemotherapy. Clin. Microbiol. Rev. (1997) 10:674-693.
57. PAHWA S, BIRON K, LIM W et al.: Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA (1988) 260:2879-2882.
58. SAINT-LEGER E, CAUMES E, BRETON G et al.: Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin. Infect. Dis. (2001) 33:2061-2067.
59. MORFIN F, THOUVENOT D, DE TURENNE-TESSIER M et al.: Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob. Agents Chemother. (1999) 43:2412-2416.
60. BOIVIN G, EDELMAN CK, PEDNEAULT L, TALARICO CL, BIRON KK, BALFOUR HH JR: Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J. Infecti. Dis. (1994) 170:68-75.
61. TALARICO CL, PHELPS WC, BIRON KK: Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J. Virol. (1993) 67:1024-1033.
62. FILLET AM, DUMONT B, CAUMES E et al.: Acycolvir-resistant varicella-zoster virus: Phenotypic and genetic characterization. J. Med. Virol. (1998) 55:250-254.
63. NEYTS J, DE CLERCQ E: Mechanism of action of acyclic nucleoside phosphonates against herpesvirus replication. Biochem. Pharmacol. (1994) 47:39-41.
64. CIHLAR T, CHEN MS: Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. (1996) 50:1502-1510.
65. CRUMPACKER CS: Mechanism of action of foscarnet against viral polymerases. Am. J. Med. (1992) 92:3S-7S.
66. DERAY G, MARTINEZ F, KATLAMA C et al.: Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am. J. Nephrol. (1989) 9:316-321.
67. SJOVALL J, KARLSSON A, OGENSTAD S, SANDSTROM E, SAARIMAKI M: Pharmacokentics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin. Pharmacol. Ther. (1988) 44:65-73.
68. WAGSTAFF AJ, BRYSON HM: Foscarnet:. reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs (1994) 48:199-226.
69. WATHEN MW: Non-nucleoside inhibitors of herpesviruses. Rev. Med. Virol. (2002) 12:167-178.
70. MCGUIGAN C, BARUCKI H, BLEWETT S et al.: Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J. Med. Chem. (2000) 43:4993-4997.
71. MCGUIGAN C, BRANCALE A, BARUCKI H et al.: Furano pyrimidines as novel potent and selective and-VZV agents. Antiviral Chem. Chemother. (2001) 12:77-89.
72. BALZARINI J, MCGUIGAN C: Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication. J. Antimicrob. Chemother. (2002) 50:5-9.
73. SIENAERT R, NAESENS L, BRANCALE A, DE CLERCQ E, MCGUIGAN C, BALZARINI J: Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol. Pharm. (2002) 61:249-254.
74. BALZARINI J, SIENAERT R, LIEKENS S et al.: Lack of susceptibility of bicyclic nucleoside analop, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol. Pharm. (2002) 61:1140-1145.
75. DIASIO RB: Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br. J. Clin. Pharmacol. (1998) 46:1-4.
76. OKUDA H, OGURA K, KATA A et al.: A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Ther. (1998) 287:791-799.
77. HOLY A, VOTRUBA I, MASOJIDKOVA M et al.: 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J. Med. Chem. (2002) 45:1918-1929.
78. BRIDEAU RJ, KNECHTEL ML, HUANG A et al.: Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. (2002) 54:19-28.
79. KNECHTEL ML, HUANG A, VAILLANCOURT VA, BRIDEAU RJ: Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline. J. Med. Virol. (2002) 68:234-236.
80. OIEN NL, BRIDEAU RJ, HOPKINS TA et al.: Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. (2002) 46:724-730.
81. TUCKER JA, CLAYTON TL, CHIDESTER CG et al.: Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors. Bioorg. Med. Chem. (2000) 8:601-615.
82. VAILLANCOURT VA, CUDAHY MM, STALEY SA et al.: Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg. Med. Chem. Let. (2000) 10:2079-2081.
83. THOMSEN DR, OIEN NL, HOPKINS TA et al.: Amino acid changes within conserved region III of the herpes simpler virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J. Virol. (2003) 77:1868-1876.
84. VAN ZEIJL M, FAIRHURST J, JONES TR et al.: Novel class of thiourea compounds that inhibit herpes simplex virus Type 1 DNA cleavage and encapsidation: Resistance maps to the UL6 gene. J. Virol. (2000) 74:9054-9061.
85. VISALLI RJ, FAIRHURST J, SRINIVAS S et al.: Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J. Virol. (2003) 77:2349-2358.
86. BROWN JC, MCVOY MA, HOMA FL: Packaging DNA into herpesvirus capsids. In: Structure-function relationships of human pathogenic viruses. Holzenburg, Bogner (Eds), Kluwer academic/Plenum, New York, USA. (2002):111-153.
87. NEWCOMB WW, BROWN JC: Inhibition of herpessimplex virus replication by WAY-150138: Assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J. Virol. (2002) 76:10084-10088.
88. L6 gene product forms the portal for entry of DNA into the herpessimplex virus capsid. J. Virol. (2001) 75:10923-10932.
89. BETZ UA, FISCHER R, KLEYMANN G, HENDRIX M, RUBSAMEN-WAIGMANN H et al.: Potent in vivo antiviral activity of the herpessimplex virus primase-helicase inhibitor BAY-571293. Antimicrob. Agents. Chemother. (2002) 46:1766-1772.
90. KLEYMANN G, FISCHER R, BETZ UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpessimplex disease. Nat. Med. (2002) 8:392-398.
91. CRUTE JJ, GRYGON CA, HARGRAVE KD et al.: Herpessimplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. (2002) 8:386-391.
92. DE CLERCQ E: Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-d]pyrimidine nucleoside analogues. Med. Res. Rev. (2003) 23:253-274.